Manchester and London, UK, 11 June, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced the appointment of Piers Morgan as Chief Executive Officer with immediate effect. Mr Morgan has also been appointed to the Company's Board of Directors. He succeeds Dr Sam Williams, who returns to his previous role as a Non-Executive Director of the Company.
Manchester, UK, November 10 2013 – C4X Discovery (C4XD), a leader in conformational drug discovery and design, announces the publication of a new peer-reviewed paper in Drug Discovery Today examining the use of its technology in structure-based drug design1. This paper follows the recent publication of the first peer-reviewed description of C4XD’s technology in Bioorganic & Medicinal Chemistry2.
Manchester, UK, September 23 2013 – C4X Discovery (C4XD), a leader in conformational drug discovery and design, is to collaborate with the University of Southampton on rational design of novel drug candidates derived from cyclic peptides. Led by Dr Ali Tavassoli, a world expert in this area1,2, researchers at the University have discovered new blockers3 of a protein-protein interaction in viral budding, a key step in the process by which HIV spreads in the body. The partners will use C4XD's 4D NMR technology to analyse the active confirmation of the inhibitors, with this enhanced understanding of activity leading to optimised second-generation compounds with more drug-like properties.
Manchester, UK, August 28 2013 – C4X Discovery (C4XD; formerly Conformetrix), a leader in conformational drug discovery and design, is highlighting at two conferences in September the potential of its dynamic NMR technology to provide significant conformational insights. Following on from the company's recent announcement that it has solved the solution-structure of a Class B GPCR ligand in one week, the presentations will provide further insight into how the 4D structures generated by the company's MolGyrate technology can be used in drug design.
Manchester, UK, August 20 2013 – C4X Discovery (C4XD), a leader in conformational drug discovery and design, has used its proprietary NMR-based technology to solve the dynamic solution-structure of a small molecule antagonist of the Class B GPCR corticotropin-releasing factor receptor (CRF-1R) in just seven days. The results add to the recent co-crystal structure of the same antagonist bound to CRF-1R, providing new insights into its binding properties and illustrating the invaluable role that C4XD's technology can play in rational drug design.
Manchester, UK, July 17 2013 – C4X Discovery (C4XD), a leader in conformational drug discovery and design, announces the publication of a seminal paper describing the use of its novel NMR-based technology to determine the dynamic 3D structures of ligand molecules in solution. The publication in Bioorganic & Medicinal Chemistry1 is the first peer-reviewed description of the technology and demonstrates its potential value in drug discovery and development.
Manchester, UK, July 8 2013 – To reflect an increased recognition of the impact of its 3D NMR technology on drug discovery and optimisation, C4X Discovery has been chosen as the new name for Conformetrix.
Manchester, UK, December 17 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, is pleased to announce progress in its lead proprietary programme, focused on selective inhibition of the orexin-1 receptor (OX1R). The company has generated a series of potent antagonists, which it plans to evaluate and progress to drug leads. Orexin is a neurotransmitter believed to play a role in a broad range of behavioural conditions, from sleep disorders to addiction.